Henrik Grönberg

Henrik Grönberg

Professor/Överläkare
E-postadress: henrik.gronberg@ki.se
Telefon: +46852482347
Besöksadress: Nobels väg 12a, 17165 Solna
Postadress: C8 Medicinsk epidemiologi och biostatistik, C8 MEB Grönberg, 171 77 Stockholm
Del av:

Om mig

  • Henrik Grönberg är professor i klinisk cancerepidemiologi vid Karolinska Institutet och överläkare på Prostatacancer centrum Capio S;t Görans sjukhus som han startade 2017. Han leder en omfattande forskarmiljö inom prostatacancer med cirka 50–60 medarbetare, bestående av kliniker, statistiker, bioinformatiker och forskare inom artificiell intelligens.

    Forskningsverksamheten bedrivs i nära samarbete med Martin Eklund,  Johan Lindberg och Tobias Nordström. Tillsammans utvecklar de en integrerad forskningsmiljö med fokus på förbättrad diagnostik och behandling av prostatacancer.

    Forskargruppens övergripande mål är att utveckla metoder för diagnostik, prognostik och behandlingsprediktion vid prostatacancer. Arbetet baseras på en kombination av storskaliga kliniska studier, analys av genomiska data samt utveckling och tillämpning av AI-baserade metoder, med syfte att bidra till en mer individanpassad vård.

    ProBio-studien är en adaptiv, biomarkörstyrd plattformstudie för patienter med metastaserad prostatacancer. Studien syftar till att utvärdera och optimera behandlingsstrategier baserat på tumörens molekylära profil genom en studiedesign där flera behandlingar kan testas parallellt och successivt anpassas utifrån inkommande data.

    Henrik Grönberg har även haft en central roll i utvecklingen av de populationsbaserade screeningstudierna STHLM3 och STHLM3-MR. STHLM3-studien visade att en kombination av biomarkörer, genetiska markörer och kliniska variabler kan förbättra detektion av kliniskt signifikant prostatacancer jämfört med PSA-testning. I den efterföljande STHLM3-MR-studien integrerades magnetkameraundersökning (MR) i screeningstrategin, vilket bidrog till ökad diagnostisk precision och minskning av onödiga biopsier.

    Grönberg har utsetts till Årets cancerforskare. Utöver sin forskning har Henrik Grönberg varit prefekt för Institutionen för medicinsk epidemiologi och biostatistik (MEB) 2008-2013 vid samt tjänstgjort som vikarierande prorektor 2016 vid Karolinska Institutet.

Utvalda publikationer

Artiklar

Alla övriga publikationer

Forskningsbidrag

  • Swedish Research Council
    1 december 2025 - 30 november 2029
    This study assesses the feasibility and clinical benefits of de‐escalating treatment in metastatic hormone‐sensitive prostate cancer (mHSPC) patients with undetectable circulating tumor DNA (ctDNA). In an open-label, 1:1 randomized, non-inferiority trial, we compare darolutamide monotherapy to the standard combination of androgen deprivation therapy (ADT) plus darolutamide.The primary endpoint is time to development of castration resistance, analyzed using Bayesian Weibull accelerated failure time models, while secondary endpoints include health-related quality of life (HR-QOL), testosterone recovery, bone health, and cost-effectiveness.Leveraging the established ProBio trial platform—with ongoing recruitment across Sweden, Belgium, Norway, and Switzerland and over 940 patients enrolled—the study aims to reduce ADT-associated adverse effects without compromising efficacy. Coordinated by experienced investigators at Karolinska Institutet and supported by a finalized drug supply contract with Bayer, approximately 400 patients will be enrolled over 2–3 years with interim analyses planned.If successful, this de-escalation strategy may establish a new treatment paradigm for mHSPC patients with favorable prognosis, improving quality of life while maintaining robust clinical outcomes.This abstract and tstudy proposal is a summary of the 20-page sub-protocol: ProBio-Darolutamide monotherapy. The full protocol is available after request to: henrik.gronberg@ki.se.
  • Cancerfonden
    1 januari 2025 - 31 december 2027
  • Cancerfonden
    1 januari 2024 - 31 december 2026
  • Cancerfonden
    1 januari 2022 - 31 december 2024
  • Swedish Research Council
    1 januari 2022 - 31 december 2025
  • Swedish Research Council
    1 januari 2021 - 31 december 2024
  • Swedish Research Council
    1 januari 2020 - 31 december 2023
  • Swedish Research Council
    1 januari 2020 - 31 december 2020
  • VINNOVA
    15 mars 2019 - 31 december 2021
  • Nordic implementation of personalised prostate cancer diagnostics
    NordForsk
    1 januari 2019 - 31 december 2020
  • Swedish Research Council
    1 januari 2019 - 31 december 2022
  • Swedish Research Council
    1 januari 2019 - 31 december 2021
  • Tomorrow's Prostate Diagnostics - A Highly Improved Diagnosis That Leads to Reduced Over and Under Diagnosis and Improved Survival in Sweden's Most Common Cancer
    Swedish Cancer Society
    1 januari 2018
    Prostate cancer is Sweden's most common cancer. Each year, over 10,000 men suffer from prostate cancer and 2,300 die from their disease. Unfortunately, today's diagnostics are substandard. This means that many men are over-treated while many aggressive and demanding prostate cancers are never treated. In recent years, our and others' research has shown that prostate cancer diagnosis can be improved by using the Stockholm3 test instead of PSA, improving the tissue sampling with magnetic camera followed by targeted biopsies and by genomically analyzing the tumor to choose the right treatment. My research group has identified the three key areas in prostate cancer diagnostics where we believe that improvements provide the most value for future patients. First, we will validate the Stockholm3 test in various healthcare systems within the EU. On the one hand, we carry out a randomized clinical study that can provide a basis for the National Board of Health and Welfare to introduce screening for prostate cancer. Finally, we will carry out a large randomized study that provides molecular support for the choice of treatment if one is to suffer from spread prostate cancer. All studies will be carried out at high speed to bring value to patients of the future as soon as possible. If we succeed with our academically driven studies, these will have a great impact on healthcare. For the patient, this means that in the near future we will be able to greatly reduce over- and under-diagnosis while at the same time increasing the survival of prostate cancer. For society, this will mean lower costs for diagnosis and care of prostate cancer and that critical resources in urology, pathology and oncology are used in a better way and more fairly.
  • Swedish Research Council
    1 januari 2018 - 31 december 2020
  • Swedish Research Council
    1 december 2017 - 31 december 2020
  • Clinical implementation of genetic markers in prostate cancer
    Swedish Cancer Society
    1 januari 2017
    Prostate cancer is the most common cancer in men in Sweden today and over 10,000 men are diagnosed annually. Over 2,500 men die from prostate cancer, making it the most common cancer-related cause of death in Sweden. One way to reduce mortality is to diagnose prostate cancer as early as possible. Today, the PSA test is used, but we have now developed a better combined test STHLM3 test that is clearly better than PSA. We work on developing the diagnosis of prostate cancer and in the best way find the prostate cancers that are dangerous and need treatment. We use several different statistical and molecular genetic methods. Our research deals with a disease that is of great importance since over 2,500 men die in prostate cancer in Sweden annually. With our studies we try to develop various tests that enable us to find and treat the more dangerous cancers as early as possible. With this research program we want:   • Further develop the STHLM3 test • Evaluate how to combine the STHLM3 test with MRI (MRI) • Develop a tumor test that can determine whether a man needs treatment or not for his prostate cancer
  • Clinical implementation of genetic markers in prostate cancer
    Swedish Cancer Society
    1 januari 2016
    Prostate cancer is the most common cancer in men in Sweden today and over 10,000 men are diagnosed annually. Over 2,500 men die from prostate cancer, making it the most common cancer-related cause of death in Sweden. One way to reduce mortality is to diagnose prostate cancer as early as possible. Today, the PSA test is used, but we have now developed a better combined test STHLM3 test that is clearly better than PSA. We work on developing the diagnosis of prostate cancer and in the best way find the prostate cancers that are dangerous and need treatment. We use several different statistical and molecular genetic methods. Our research deals with a disease that is of great importance since over 2,500 men die in prostate cancer in Sweden annually. With our studies we try to develop various tests that enable us to find and treat the more dangerous cancers as early as possible. With this research program we want:   • Further develop the STHLM3 test   • Evaluate how to combine the STHLM3 test with MRI (MRI)   • Develop a tumor test that can determine whether a man needs treatment or not for his prostate cancer
  • Swedish Research Council for Health Working Life and Welfare
    1 januari 2016 - 31 december 2018
  • Swedish Research Council
    1 januari 2016 - 31 december 2018
  • Clinical implementation of genetic markers in prostate cancer
    Swedish Cancer Society
    1 januari 2015
    Prostate cancer is the most common cancer in men in Sweden today and over 10,000 men are diagnosed annually. Over 2,500 men die from prostate cancer, making it the most common cancer-related cause of death in Sweden. One way to reduce mortality is to diagnose prostate cancer as early as possible. Today, the PSA test is used, but we have now developed a better combined test STHLM3 test that is clearly better than PSA. We work on developing the diagnosis of prostate cancer and in the best way find the prostate cancers that are dangerous and need treatment. We use several different statistical and molecular genetic methods. Our research deals with a disease that is of great importance since over 2,500 men die in prostate cancer in Sweden annually. With our studies we try to develop various tests that enable us to find and treat the more dangerous cancers as early as possible. With this research program we want:   • Further develop the STHLM3 test • Evaluate how to combine the STHLM3 test with MRI (MRI) • Develop a tumor test that can determine whether a man needs treatment or not for his prostate cancer
  • Visa fler

Anställningar

  • Professor/Överläkare, Cancerepidemiologi, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2020-
  • Professor, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2019-2020
  • Professor/Överläkare, Cancerepidemiologi, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2015-2019
  • Professor/Överläkare, Universitetsgemensamt, Karolinska Institutet, 2016-2016
  • Professor, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2005-2015

Handledning

  • Handledning till doktorsexamen

    • Andreas Karlsson, Microsimulation modelling of prostate cancer screening in Sweden., 2019

Nyheter från KI

Kalenderhändelser från KI